Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 3Neurotoxicity Syndromes 1Neoplasm, Residual 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Central Nervous System Neoplasms 1

Interventions

motexafin gadolinium 1irinotecan sucrosofate 1bemcentinib 1Vincristine 1Temozolomide 1Rituximab 1Radiotherapy 1Radiation 1Procarbazine 1Postoperative Period 1Pemetrexed 1Nivolumab 1Methotrexate 1Memantine 1Irinotecan 1Immunotherapy 1Donepezil 1Cytarabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Central Nervous System Neoplasms × Cytarabine × Clear all
NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡